Seeking Alpha

Celsion rises on positive ThermoDox data

  • Celsion (CLSN) shares +4.2% after saying that the latest data from a Phase III study of its ThermoDox treatment for hepatocellular carcinoma (HCC), the most common type of liver cancer, continues to show that the product improves progression-free and overall survival rates.
  • ThermoDox significantly improves the latter in patients with single lesions if they undergo Radiofrequency Ablation (RFA) for 45 minutes or more. Ablation is the removal of biological tissue. (PR)
Comments (1)
  • hessed
    , contributor
    Comment (1) | Send Message
    I always trust in $CLSN
    The stock will fly to $4 soon
    I love you baby come on
    16 Sep 2013, 09:16 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: